Jul 06, 2013, 02.50 PM | Source: CNBC-TV18
Gautam Sinha Roy of Motilal Oswal Securities expects 7-8 percent upside in Lupin in near term.
Gautam Sinha Roy (more)
VP-Equity Strategy & Product, Motilal Oswal | Capital Expertise: Equity - Fundamental
"So, lot of positive tailwinds are there for Lupin. That is the main reason why we continue to like this stock at this point of time," he added.
Axis Bank | ICICI Bank | Lupin | Adani Enterprises
Drug major Lupin has received approval from the US
Lupins Diclofenac capsules are generic versions of
Lupin's subsidiary Lupin Pharmaceuticals, Inc has
Mitesh Thacker of miteshthacker.com is of the view